CELLECTIS SA And Murinus GmbH Enter Into A License Agreement For The Use Of The Homologous Recombination In Generating Mouse Models 
10/19/2005 5:11:23 PM

Cellectis, the rational genome engineering company, and Murinus GmbH announced today they have entered into a non-exclusive license agreement. Cellectis has granted Murinus rights under its patent family relating to the use of homologous recombination for the specific replacement or insertion of a gene in the mouse genome. Through this agreement, Murinus obtained a license under Cellectis patents for developing and selling, in Europe and Middle-East, genetically modified mice for industry and academia. Financial terms and conditions of the agreement were not disclosed.